Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research

Komiya,Akira; Kato,Tomonori; Hori,Takashi; Fukuoka,Junya; Yasuda,Kenji; Fuse,Hideki

doi:10.3892/ijo.2013.2173

Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research

Authors:
- Akira Komiya
- Tomonori Kato
- Takashi Hori
- Junya Fukuoka
- Kenji Yasuda
- Hideki Fuse
View Affiliations

Affiliations: Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan, Laboratory of Pathology, Toyama University Hospital, Toyama, Japan, Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Published online on: November 13, 2013 https://doi.org/10.3892/ijo.2013.2173
Pages: 195-202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tissue microarrays were constructed using prostate needle biopsy specimens obtained from 58 patients who underwent radical prostatectomy for localized or locally advanced prostate cancer (PC). We used the spiral array (SA) technique, a novel approach for tissue array construction in a spiral form, which has advantages over small needle biopsy specimens. Roll-shaped tissue pieces produced by slicing a prostate biopsy tissue block and trimming the cancer segment were used to obtain a tissue array block. Cancer segments measuring >3 mm were incorporated into the tissue arrays. Cancer fragments (n=253) were obtained from formalin-fixed, paraffin-embedded needle biopsy specimens. The median number of cancer fragments per patient was four (1-8, min-max). On SA, the median number of confirmed cancer fragments per patient was four (1-7) and 224 cancer fragments (88.5%) were confirmed histologically. Each core of reeled tissue contained at least one cancer fragment. The expressions of multiple prognostic molecular markers for PC (Ki-67, p53 and bcl-2) were immunohistochemically measured using the SA. The Ki-67 and bcl-2 expressions were significantly associated with the Gleason score (GS). A univariate analysis identified Ki-67, bcl-2 and GS as significant predictors of cancer-specific survival, p53 and bcl-2 as significant predictors of overall survival and Ki-67, adjuvant androgen deprivation and GS as significant predictors of biochemical progression. In a multivariate analysis, p53 was independently associated with overall survival, while adjuvant androgen deprivation and GS were associated with biochemical progression. These results indicate that SA has potential as a new tool for translational research on PC.

View Figures

View References

1.	Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microar-rays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998. View Article : Google Scholar : PubMed/NCBI
2.	Kallioniemi OP, Wagner U, Kononen J and Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 10:657–662. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Braunschweig T, Chung JY and Hewitt SM: Perspectives in tissue microarrays. Comb Chem High Throughput Screen. 7:575–585. 2004. View Article : Google Scholar
4.	Tsurutani J, Fukuoka J, Tsurutani H, et al: Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol. 24:306–314. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Fukuoka J, Dracheva T, Shih JH, et al: Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol. 38:276–283. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Fukuoka J, Fujii T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 10:4314–4324. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Tsuna M, Kageyama S, Fukuoka J, et al: Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma. Anticancer Res. 29:2547–2554. 2009.PubMed/NCBI
8.	Rubin MA: Use of laser capture microdissection, cDNA micro-arrays, and tissue microarrays in advancing our understanding of prostate cancer. J Pathol. 195:80–86. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Rubin MA, Dunn R, Strawderman M and Pienta KJ: Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol. 26:312–319. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Inoue T, Segawa T, Shiraishi T, et al: Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology. 66:332–337. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Yasuda K, Komiya A, Watanabe A, et al: Expression of hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer. Anticancer Res. 33:575–581. 2013.PubMed/NCBI
12.	Komiya A, Yasuda K, Nozaki T, Fujiuchi Y, Hayashi S and Fuse H: Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma. Oncol Lett. 5:53–56. 2013.PubMed/NCBI
13.	Komiya A, Yasuda K, Watanabe A, Fujiuchi Y, Tsuzuki T and Fuse H: The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients. Mol Clin Oncol. 1:257–262. 2013.
14.	Fukuoka J, Hofer MD, Hori T, et al: Spiral array: a new high-throughput technology covers tissue heterogeneity. Arch Pathol Lab Med. 136:1377–1384. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Zellweger T, Gunther S, Zlobec I, et al: Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer. 124:2116–2123. 2009.
16.	Miyake H, Muramaki M, Kurahashi T, Takenaka A and Fujisawa M: Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol. 28:145–151. 2010. View Article : Google Scholar
17.	Oxley JD, Winkler MH, Parry K, Brewster S, Abbott C and Gillatt DA: p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int. 89:27–32. 2002. View Article : Google Scholar : PubMed/NCBI
18.	Ecke TH, Schlechte HH, Schiemenz K, et al: TP53 gene mutations in prostate cancer progression. Anticancer Res. 30:1579–1586. 2010.PubMed/NCBI
19.	Nariculam J, Freeman A, Bott S, et al: Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian J Androl. 11:109–118. 2009.
20.	Cho IC, Chung HS, Cho KS, et al: Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis. Cancer Res Treat. 42:157–162. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Fleischmann A, Huland H, Mirlacher M, et al: Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene. Prostate. 72:991–997. 2012. View Article : Google Scholar : PubMed/NCBI
22.	Abdollah F, Suardi N, Cozzarini C, et al: Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol. 63:998–1008. 2013. View Article : Google Scholar
23.	Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ and Mason MD: Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. CD0060192006.PubMed/NCBI
24.	Chun FK, Steuber T, Erbersdobler A, et al: Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol. 49:820–826. 2006. View Article : Google Scholar
25.	Imamoto T, Utsumi T, Takano M, et al: Development and external validation of a nomogram predicting the probability of significant gleason sum ppgrading among Japanese patients with localized prostate cancer. Prostate Cancer. 2011:7543822011. View Article : Google Scholar : PubMed/NCBI
26.	Camp RL, Charette LA and Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest. 80:1943–1949. 2000. View Article : Google Scholar : PubMed/NCBI
27.	Kyndi M, Sorensen FB, Knudsen H, et al: Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol. 47:591–599. 2008.PubMed/NCBI